Publicaciones en colaboración con investigadores/as de Karolinska University Hospital (8)

2024

  1. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221

2022

  1. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

    European Journal of Cancer, Vol. 174, pp. S116

  2. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

2016

  1. Factors Associated with Early Mortality in Patients Treated with Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 94, Núm. 3, pp. 612-620

2015

  1. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis

    International Journal of Radiation Oncology Biology Physics, Vol. 91, Núm. 1, pp. 133-139

2013

  1. Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review

    Critical Reviews in Oncology/Hematology, Vol. 85, Núm. 2, pp. 149-161

  2. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis

    International Journal of Radiation Oncology Biology Physics, Vol. 85, Núm. 2, pp. 444-450